Clinical Trial Update: A Study of LY2880070 in Participants With Advanced or Metastatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Esperas Pharma completed a Phase 1/2 study of LY2880070 in adults with advanced or metastatic cancer, including colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colon Cancer
• Colorectal Cancer
• Endometrial Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Soft Tissue Sarcoma
• Triple-negative Breast Cancer

Drugs mentioned

• LY2880070

Snippet

Sponsor: Esperas Pharma Inc. | Conditions: Solid Tumors, Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED